natgillin/translations-raw huggingface dataset:
a frame parser configured to obtain a signal frame from the demodulated signals, the signal frame comprising preamble symbols and data symbols, a demapper configured to demap the obtained signal frame into bits for the preamble symbols and bits for the data symbols; and a decoder configured to decode the bits for the preamble symbols by a shortened and punctured LDPC(low density parity check) decoding scheme, characterized in that the receiver is configured to process signals wherein the preamble symbols are divided into at least one Layer 1 (L1) blocks, bandwidth of the L1 block corresponding to a number of active subcarriers assigned to a single channel. 
Uređaj za prijam radiotelevizijskog signala, naznačen time, što uređaj obuhvaća: sredstva za prijam signalnog okvira koji uključuje simbole preambule i barem jedan podatkovni odsječak temeljen na simbolu podatkovnog servisa; sredstva za demodulaciju primljenog signalnog okvira korištenjem metode multipleksiranja s ortogonalnom podjelom frekvencija (OFDM); sredstva za premapiranje simbola preambule u podatkovne bitove preambule, te simbole podatkovnog servisa u bitove podatkovnog servisa; i sredstva za dekodiranje bitova preambula korištenjem skraćene i bušene LDPC (provjera pariteta niske gustoće) sheme dekodiranja; pri čemu su simboli preambule podijeljeni u frekvencijske osi u blokove sloja 1 (L1) iste širine pojasa, a širina pojasa pojedinog LI bloka odgovara jednom od 3408 podnosilaca pridijeljenih jednom kanalu.
The present invention in the preferred aspect thereof provides a peptide consisting of a sequence that is selected from the group of SEQ ID No. 4 and SEQ ID No. 5. 
Farmaceutski sastav prema zahtjevu 1, koji nadalje uključuje najmanje jedan dodatni peptid koji sadrži slijed aminokiselina odabranog iz skupine koja se sastoji od SEQ ID NO 1 te SEQID NO 4 do SEQ ID NO 12.
Moreover, by virtue of an appropriate circuit configuration, the data transmission device provides for continuously testing its own operation with no interruption in data transmission to the beacons. 
Štoviše, na temelju odgovarajuće konfiguracije komunikacijskih krugova, naprava za prijenos podataka omogućuje kontinuirano testiranje svog vlastitog rada bez ikakvog prekidanja prijenosa podataka prema balizama.
optionally subjecting the second mixture to crystallization, chromatography, or extraction in order to obtain 4, or the phosphorous-based diastereomer thereof. 
po izboru podvrgavanje druge smjese kristalizaciji, kromatografiji, ili ekstrakciji u cilju dobivanja 4, ili dijastereomera toga spoja na bazi fosfora.
The reaction mixture is evaporated in vacuo, to remove MeOH then cooled in an ice bath and acidified with concentrated HCI. 
Reakcijsku smjesu se ispari u vakuumu da se odstrani MeOH, zatim se ohladi u ledenoj kupelji i zakiseli s koncentriranom HCI.
The method according to claim 9, where the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered in combination with at least one additional anti-tumour substance selected from the group consisting of cisplatin, oxaliplatin, carboplatin, valrubicin, idarubicin, doxorubicin, pirarubicin, irinotecan, topotecan, amrubicin, epirubicin, etoposide, mitomycin, bendamustine, chlorambucil, cyclophosphamide, ifosfamide, carmustine, melphalan, bleomycin, olaparib, MEDI4736, AZD1775 and AZD6738. 
Spoj s formulom (I) ili njegova farmaceutski prihvatljiva sol, za upotrebu za liječenje raka, prema zahtjevu 15, naznačen time da se spoj s formulom (D, ili njegova farmaceutski prihvatljiva sol primjenjuje u kombinaciji s najmanje jednom dodatnom protu-tumorskom tvari odabranom iz skupine koju čine cisplatin, oksaliplatin, karboplatin, valrubicin, idarubicin, doksorubicin, pirarubicin, irinotekan, topotekan, amrubicin, epirubicin, etopozid, mitomicin, bendamustin, klorambucil, ciklofosfamid, ifosfamid, karmustin, melfalan, bleomicin, olaparib, MEDI4736, AZD1775 1 AZD6738.
Figures 7a and 7b show schematically a dispensing valve 30 according to the invention. 
Slike 7a i 7b prikazuju shematski ventil za točenje 30 koji se koristi u sklopu za točenje prema izumu.
P1 agonists such as Fingolimod, CS-0777 from Sankyo and R-3477 from Actelion, hh) Interferons comprising Interferon beta 1 a such as Avonex from Biogen Idec, CinnoVex from CinnaGen and Rebif from EMD Serono, and Interferon beta 1b such as Betaferon from Schering and Betaseron from Berlex, 
T) -SIPI antagonista kao što su Fingolimod, CS-0777 iz tvrtke Sankyo i R-3477 iz tvrtke Actelion, hh) Interferona koje čine interferon beta la kao što su Avonex iz tvrtke Biogen Idec, CinnoVex iz tvrtke CinnaGen i Rebif iz tvrtke EMD Serono, i interferon beta 1 b kao što su Betaferon iz tvrtke Schering i Betaseron iz tvrtke Berlex,
As a rule, preferably, it is processed in a manner that one cuts transversely, in particular perpendicularly to a plane which is defined by the adhesion layers. 
Kao pravilo, poželjno je, da se postupa na takav način, da se reže popreko, naročito okomito na ravninu koja je definirana slojevima ljepila.
The recombinant anti-a4 antibody molecule, or a4-binding fragment thereof, for use according to claim 5, wherein the patient has an inflammatory disorder. 
Rekombinantna molekula protutijela ili njezin fragment koji veže a4, za uporabu prema zahtjevu 3, naznačena time, da pacijent ima rak.
<400> 20 A pharmaceutical composition comprising the peptide with SEQ ID NO 1 and the peptide with SEQ ID NO 2, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav koji sadrži peptid koji se sastoji od slijeda aminokiselina SEQ ID NO 2 i peptid koji se sastoji od slijeda aminokiselina SEQ ID NO 3, te farmaceutski prihvatljiv nositelj.
The receiver of any one of claims 9 to 11, wherein bit and time deinterleaving processes are not performed on the layer 1. 
Prijamnik iz bilo kojeg od patentnih zahtjeva 9 do 11, pri čemu postupci raspletanja bitova i vremena nisu izvedeni narazini 1.
A compound according to claim 1 that is 9-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-methyl-2,3,4,5-tetrahydropyrido[2,3-f][1,4]oxazepine or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]furo[3,4-b]piridin-5(7H)-on ili njegova farmaceutski prihvatljiva sol.
The oligonucleotide decoy of claim 7, further comprising a third transcription factor binding site, wherein said third transcription factor binding site binds to a transcription factor selected from the group consisting of POU1F1, POU2F, POU3F, POU5F1, USF, EGR1, CREB/ATF, AP1, CEBP, SRF, ETS1, MEF2, SP1, RUNX, NFAT, ELK1, ternary complex factors, STAT, GATA1, ELF1, nuclear factor-granulocyte/macrophage a, POU4F1, HNF1, ZFHX3, IRF, TEAD1, TBP, NFY, caccc-box binding factors, KLF4, KLF7, IKZF, MAF, REST, HSF, KCNIP3 and PPAR transcription factors. 
Oligonukleotidna zamka prema zahtjevima 1 do 3, naznačena time, da nadalje obuhvaća treće mjesto spajanja faktora transkripcije, pri čemu se navedeno treće mjesto spajanja faktora transkripcije, spaja na faktor transkripcije odabran iz skupine faktora transkripcije koju čine: POU1F1, POU2RF, POU3F, POU5F1, USF, EGR1, CREB/ATF, AP1, CEBP, SRF, ETS1, MEF2, SP1, RUNX, NFAT, ELK1, ternalni kompleksni faktori, STAT, GATA1, ELF1, nuklearni faktor-granulocita/makrofaga, POU4F1, HNF1, ZFHX3, IRF, TEAD1, TBP, NFY, faktori spajanja caccc-box-a, KLF4, KLF7, IKZF, MAF, REST, HSF, KCNIP3 i PPAR.
At the moment of its use, the capsule is loaded in a machine, where said upper wall is perforated so as to enable water under pressure to be let into the capsule, while another piercing device provides a plurality of orifices in said reduced-thickness zones of the bottom wall. 
Prilikom upotrebe kapsulu se umeće u stroj, gdje se navedenu stropnicu perforira, čime se omogućuje da voda pod tlakom uđe u kapsulu, dok drugi uredaj za probadanje pravi više otvora u navedenim zonama smanjene debljine u podnici.
The method of claim 3, wherein the mouse constant region gene comprises a sequence selected from a CH1, a hinge, a CH2, a CH3, a CH4, and a combination thereof. 
Miš u skladu s patentnim zahtjevom 5, naznačen time, da gen konstantne regije glodavaca sadržava gensku sekvencu mišje konstantne regije odabranu između CH1, zgloba, CH2, CH3, CH4 i njihove kombinacije.
The polypeptide for use of any preceding claim, wherein the polypeptide is a fusion protein including, in addition to a variant ActRIIB polypeptide domain, a polypeptide portion selected from the group consisting of: an immunoglobulin Fc domain and a serum albumin. 
Polipeptid za uporabu prema bilo kojem od prethodnih zahtjeva, pri čemu je polipeptid fuzijski protein uključujući, kao dodatak varijanti ActRIIB domene polipeptida, dio polipeptida odabran od skupine koja se sastoji od: domene imunoglobulina Fc 1 albumin seruma.
The compound for use according to claim 1 wherein R-A is selected from 
Spoj prema patentnom zahtjevu 1 naznačen time što R-A je izabran od [image] [image] ili [image]
A compound according to claim 1 or 2, wherein any Ar may be substituted with one or more substituents independently selected among halogen, C1-6-alk(en/yn)yl, halo-C1-6-alk(en/yn)yl and C1-6-alk(en/yn)yloxy. 
Spoj prema bilo kojem od patentnih zahtjeva 1-6, naznačen time što svako Ar može biti supstituirano sa jednim ili više supstituenata koji su nezavisno izabrani od halogena, Crs-alk(en/injil, halo-C,.g-alk(enfinjil i CLs-alk(en/in)iloksi.
An antibody-like binding protein comprising two polypeptide chains that form two antigen binding sites, wherein a first polypeptide chain has a structure represented by the formula: 
Protutijelu sličan vezivni protein koji sadrži dva polipeptidna lanca koji tvore dva mjesta vezivanja antigena, pri čemu prvi polipeptidni lanac ima strukturu predstavljenu s formulom: VLi-Li-VLeLo-CL_
Phosphate salt (2) 
Fosfatna sol (2)
Described herein is a pharmaceutical kit comprising: a composition comprising a polypeptide comprising Nef or an immunogenic fragment or derivative thereof and p17 and/or p24 Gag or an immunogenic fragment or derivative thereof, wherein when both p17 and p24 Gag are present there is at least one HIV antigen or immunogenic fragment or derivative between them, together with a pharmaceutically acceptable excipient; and a composition comprising a polynucleotide encoding one or more of Nef and Gag or an immunogenic fragment or derivative ofNef or Gag containing a Nef or Gag epitope present in the polypeptide of a), together with a pharmaceutically acceptable excipient. 
THI, poput QS21 ili 3D-MPL, ili kombinacija Q521 i13D-MPL. Farmaceutski komplet, naznačen time što sadrži: a) pripravak koji sadrži polipeptid u skladu s patentnim zahtjevom 1, zajedno s farmaceutski prihvatljivom pomoćnom tvari, i b) pripravak koji sadrži polinukleotid koji kodira jedan ili više od Nef ili Gag ili imunogeni fragment ili derivat Nef ili Gag, koji sadrži epitop Nef ili Gag prisutan u polipeptidu iz a), zajedno s farmaceutski prihvatljivom pomoćnom tvari, gdje bilo koji imunogeni fragment ili derivat zadržava sposobnost poticanja imunosnog odgovora na nativni antigen, t>&
Preferably, a resiliently deformable arm extends from the blister strip locator chassis and the indexing mechanism comprises an indexing wheel rotatably mounted to the free end of the resiliently deformable arm over which a strip of blisters is passed. 
Inhalator prema zahtjevu 31, gdje se savitljivi krak (88) pruža od okvira lokatora trake blistera (84) i mehanizam označavanja (90) obuhvaća kolo za označavanje koje je pričvršćeno tako da se može okretati na slobodnom kraju savitljivog kraka (88) preko kojeg prolazi traka blistera.
In some embodiments, a therapeutically effective amount of the compound(s) and/or salt(s) is administered to the animal. 
Spoj ili sol prema zahtjevu 1, naznačen time, da: spoj odgovara strukturi formule IB-L0: (IB-LO)
From the beginning of the 1970s a special equipment is available for the preparation of pellets. 
Od početka sedamdesetih godina, za priređivanje granula načinjen je poseban uređaj.
By the combustion of the fuel in the pre-calciner unit (10) a hot zone is produced in the cyclone tower wherein the raw clinker meal is calcined. 
Postupak prema patentnom zahtjevu 1, naznačen time što se materijal od vlaknastog cementa dodaje u jedinici za predkalciniranje (10) u sirovi klinkerski kolač.
As indicated in Figure 2, controller 80 and other components could be located remotely from housing 200 (e.g. 
Kao što je prikazano na slici 2, kontrolor 80 i druge komponente mogu se postaviti na nekoj udaljenosti od kućišta 200 (npr.
202120) or as a viscosity-increasing agent (the United States Pharmacopoeia, ed. 
202120) ili kao sredstvo za povećanje viskoznosti (The United States Pharmacoposia, ed.
The composition according to claim 1, characterized in that said composition is prepared by a method as follows: preparation of #1 Extract: Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Corydalis and Semen Cassiae are mixed, extracted by using heating refluxing with 3∼6 fold of 50∼80% ethanol for 2∼3 times, the first time for 0.5∼2.5 hours, the second and/or third time for 0.5∼2 hours, and filtered to remove the impurities; and the ethanol is recovered and concentrated until the relative density is 1.250∼1.350 at 70∼80°C to give #1 Extract for later use; 
Priprema ekstrakta br. 1: Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Corydalis i Semen Cassiae se pomiješaju, ekstrahiraju uz refluks i zagrijavanje s 3 do 6 puta većom količinom 50 do 80 % etanola 2 do 3 puta, prvi put u trajanju 0,5 do 2,5 sati, drugi i / ili treći put u trajanju od 0,5 do 2 sata i filtriraju se kako bi se uklonile nečistoće; i etanol se izdvaja i koncentrira do relativne gustoće 1.250 ~ 1.350 na 70 do 80°C da se dobije ekstrakt br. 1 za kasniju uporabu; b).
The angled guide plate according to claim 1, wherein the angled guide plate is substantially trapezoidal-shaped as seen in top view, wherein a length of the supporting region is longer than a length of the guide region. 
Kutna ploča vodilice (10) prema zahtjevu 1 ili 2, naznačena time da je, u tlocrtu, kutna ploča vodilice (10) trapezoidna tako da je duljina potpornog područja (50) dulja od duljine područja vođenja (40).
The method of claim 18, wherein the at least one cell obtained in step (b) is derived from the spleen, a lymph node or bone marrow of the mouse from step (a). 
najmanje jedna stanica dobivena u koraku (b) se dobiva iz slezene, limfnog čvora ili koštane srži miša iz koraka (a); Ili
Compound for use according to Claim 3, or use according to Claim 4, wherein the infection is caused by a Gram-negative bacterium selected from Enterobactericeae, Bacteroidaceae, Vibrionaceae, Pasteurellae, Pseudomonadaceae, Neisseriaceae, Rickettsiae, Moraxellaceae, any species of Proteeae, Acinetobacter spp ., Helicobacter spp ., and Campylobacter spp .. 
Spoj za uporabu prema patentnom zahtjevu 3, ili uporabu prema patentnom zahtjevu 4, naznačen time da je zaraza uzrokovana Gram-negativnom bakterijom izabranom od FEnterobactericeae, Bacteroidaceae, Vibrionaceae, Pasteurellae, Pseudomonadaceae, Neisseriaceae, Rickettsiae, Moraxellaceae, bilo koja vrsta Proteeae, Acinetobacter spp., Helicobacter spp., i Capylobacter spp.
The compound of Formula LII is then deformylated to form a compound of Formula LIII. 
1. deformilaciju spoja Formule LII, čime se dobiva spoj Formule LIII:
dissolving or dispersing the remaining proportion of the total amount of the binder in the granulation liquid; 
- otapanje 1 raspršivanje preostalog udjela ukupne količine vezivnog sredstva u granulacijskoj tekućini;
In a preferred embodiment, said salt of a C5-C28 fatty acid is a salt of a linear fatty acid if said fatty acid is a C6-C9 fatty acid. 
Postupak prema bilo kojem zahtjevu od 1 do 9, naznačen time da navedena sol Cs - C2xg masne kiseline je sol linearne masne kiseline ako je navedena masna kiselina Cg - Ca masna kiselina.
wrapping the structure (F) by a first sleeve (S 1) made of foldable sheet material so that the sleeve envelopes a first pair of opposite frame members (H 1, H 3); and 
obavijanje okvirne konstrukcije (F) prvim omotačem (S1) izrađenim od složive folije tako da taj omotač obavija prvi par nasuprotnih okvirnih elemenata (H1, H3); i
∧1 of these subjects reported 2 different types of abnormal skin odor in the same session but is counted only once no events reported 
M od tih subjekata je prijavio 2 različita tipa abnormalnog mirisa kože u istom protokolu ali se računa samo jednom - nema prijavljenih događaja
ii) one hydrophilic polymeric component comprising reactive groups wherein i) and ii) are associated with each other so that the reactivity of the polymeric component is retained, wherein associated means that said polymeric component is coated onto a surface of said matrix of a biomaterial, or 
Hemostatska porozna kompozitna spužva koja se uglavnom sastoji od i) matrice biomaterijala i ii) jedne hidrofilne polimerne komponente koja sadrži elektrofilne reaktivne skupine, naznačena time da navedena hidrofilna polimerna komponenta je hidrofilno sredstvo za umrežavanje, pri čemu su i) i ii) međusobno povezani tako da je zadržana reaktivnost polimerne komponente, pri čemu izraz povezani znači da - < navedena polimerna komponenta je prevučena na podlogu navedene matrice biomaterijala, ili
The method according to the invention is notable in that it implements, prior to the signal generation step, the following steps: 
- > generiranje signala, koji sadrži navedene kodirane informacije, te je navedeni postupak kodiranja naznačen time da, prije navedenog koraka generiranja signala, provodi slijedeće korake:
chlorinating Compound D to afford Compound E of the formula 
c) kloriranje Spoja D radi dobivanja Spoja E formule
Apparatus according to the preceding claim, wherein a processing unit is configured for controlling the dispensing device and commanding - during each cycle of manufacturing a respective elongated body - to dispense the liquid synthetic resin mass in an amount greater than the mass amount necessary for forming said elongated body in order to generate a surplus mass destined to exit from the mould. Apparatus according to anyone of the preceding claims, comprising: 
Uređaj u skladu s prethodnim patentnim zahtjevom, naznačen time što je jedinica za obradu konfigurirana za upravljanje uređajem za izdavanje i davanje naredbi, u svakom ciklusu proizvodnje odgovarajućeg izduljenog tijela, za izdavanje mase tekuće sintetske smole u količini većoj od količine mase potrebne za oblikovanje navedenog izduljenog tijela kako bi se dobilo suvišnu masu koja treba izaći iz kalupa (2).
Specifically, these naphthyl group may have on the naphthalene ring, 1 to 3 substituents selected from the group consisting of linear or branched alkyl groups having 1 to 6 carbon atoms, halogen atoms, and amino groups that may have 1 or 2 substituents selected from the group consisting of linear or branched alkyl groups having 1 to 6 carbon atoms and linear or branched alkanoyl groups having 1 to 6 carbon atoms. Examples of the lower alkanoyl group optionally substituted by one or more halogen atoms include linear or branched alkanoyl groups having 2 to 6 carbon atoms that may have 1 to 3 halogen atoms as substituents. 
Ci alkilendioksi skupine; piridil skupine; i amino skupine koje mogu imati najmanje jedan supstituent odabran iz skupine koju čine C1g alkil skupine i Cig alkanoil skupine), opcijski halogenirane Cig alkil skupine, cikloalkil skupine, naftil skupina koja može imati na naftalen prstenu, 1 do 3 supstituenta odabrana iz skupine koju čine C1.4 alkil skupine, halogen atomi, i amino skupine opcijski supstituirane s najmanje jednim supstituentom odabranim iz skupine koju čine Ci.4 alkil skupine i Ci.4 alkanoil skupine, ili je to skupina predstavljena općom formulom:
The entire contents of the aforementioned patent applications are incorporated herein by this reference. 
EUROPSKOG PATENTA Datum objave prijevoda patentnih zahtjeva: 31.08.2012.
The immunogenic composition of claim 3 wherein the at least two further bacterial saccharide conjugates comprise N. meningitidis serogroup C capsular saccharide (MenC). 
Imunogeni pripravak u skladu s patentnim zahtjevom 3, naznačen time što najmanje dva dodatna konjugata bakterijskih saharida sadrže saharid iz kapsule bakterije N. meningitidis seroskupina € (MenC).
the pharmaceutical preparation in the suitable container is an aqueous pharmaceutical solution comprising 20mg/ml glatiramer acetate and 40mg/ml mannitol, or 40mg/ml glatiramer acetate and 40mg/ml mannitol, 
farmaceutski pripravak u prikladnom spremniku jest vodena farmaceutska otopina koja sadrži 20mg/ml glatiramer acetata i 40mg/ml manitola, ili 40mg/ml glatiramer acetata i 40mg/ml manitola, ili
In the embodiment shown in Figure 4 the data portion 3' on the data sheet is provided with a filling layer 8 to be laminated. 
U ostvarenju koje je prikazano na slici 4 predio za podatke 3", koji se nalazi na listu za podatke, snabdjeven je sa slojem za ispunu $ koji se treba slojno spojiti.
an intra prediction module for reconstructing an intra prediction mode and creating a prediction block of a current block or a sub block of the current block; 
modul (240) za intrapredikciju konfiguriran da rekonstruira intrapredikcijski režim i da kreira predikcijski blok tekućeg bloka ili podbloka tekućeg bloka;
A composition for use as a pest control agent comprising the compound according to claim 4, or an agriculturally and horticulturally acceptable salt thereof as active ingredient and an agriculturally and horticulturally acceptable carrier. 
Pripravak za upotrebu kao sredstvo za kontrolu štetočina, naznačeno time da sadrži spoj prema patentnom zahtjevu 1 ili agrikulturno ili hortikulturno prihvatljivu sol kao aktivni sastojak te agrikulturno ili hortikulturno prihvatljiv nosač.
The method of claim 9, wherein the dicarboxylic acid is maleic acid. 
Smjesa prema zahtjevu 21, gdje dikarboksilna kiselina je maleinska kiselina.
According to requirements, the sheet 10 is cut into specific formats, for example for manual packaging of sliced or whole salami and cold pork meat products, both fresh and mature, cheese in slices and pieces, both soft and matured, fresh meat, et cetera. 
Ovisno o zahtjevima, foliju 10 se reže na specifične formate, na primjer za ručno pakiranje odrezaka ili cijelih salama 1 hladnih proizvoda od svinjskog mesa, oboje svježeg 1 zrelog, sira u odrescima i komadima, oboje mekog 1 zrelog, svježeg mesa, i tako dalje.
Microtiter plates were coated with 5 ug/ml monoclonal antibody prepared against IL-18BP (monoclonals prepared as described in WO02092008 and affinity purified on a Protein G column) in coating buffer overnight at 4° C. The plates were washed three times with washing buffer and blocked with blocking buffer (see below). 
Mikrotitarske pločice obložene su sa 5 ug/ml monoklonskog antitijela protiv 1I-18BP (monoklonci su pripravljeni na način opisan u WO02092008 1 pročišćeni afinitetnom komatografijom nakoloni Protein G) u puferu za oblaganje preko noći pri 4 "C. Pločice su isprane tri puta sa puferom za ispiranje i blokirane sa puferom za blokiranje (vidi dolje).
The solid form of claim 32, wherein the crystalline compound I-1•acetone solvate has a compound I-1 to acetone ratio of about 1:0.44. 
gdje kristalni spoj I-1• aceton solvat ima omjer spoja I-1 naprama acetonu od oko 1:0,44;
The construct for the use of claim 1 or 2, wherein said acute lymphoblastic leukemia (ALL) is refractory and/or relapsed ALL. 
Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je navedena akutna limfoblastična leukemija (ALL) refrakterna i/ili recidiv ALL.
Stably transfected human GnRH receptor RBL cells are grown to confluence. 
RBL stanice stabilno transficirane ljudskim receptorom GNRH uzgajane su do konfluentnosti.
The solids were removed by filtration (pure product) and the liquid phases were separated. 
Krutina se ukloni filtriranjem (čisti produkt) i tekuće faze se odvoje.
The combination of claim 1, wherein the modified casing coupling can be serviced at the well site. 
Kombinacija iz zahtjeva 1, pri čemu je modificirana spojka za zaštitne cijevi (136) upotrebljiva na mjestu bušotine.